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ﬂowchart in Figure 3 of Bamgbola’s review revealed none of
the suggested etiologies.
As shown by our data and that of others, HD patients
exhibit a wide range of RBCLS, with almost one in six patients
having an RBCLS below 47 days. RBCLS and EPO respon-
siveness are closely related—a fact that is often neglected or
underappreciated in clinical practice. A consideration of
RBCLS is vital for interpretation of EPO responsiveness,
particularly in populations with notably variable RBCLS, such
as dialysis patients.
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The Author Replies: I read with utmost interest the cor-
respondence posted by Yanna et al.1 in the Journal in response
to the review article on erythropoietin (EPO) resistance2 that
was published on 22 June 2011. Although I strongly identify
with the premise for the argument, I disagree with the
syllogistic connotation. Indeed, the apparent lack of explicit
elaboration on red cell survival as a topic is not due to its lack
of importance but rather borne out of the near-universality of
its role in anemia.
Practically all of the etiological factors discussed in the
article are mediated by at least one of these three pathophys-
iological processes: (1) inadequate hematopoiesis; (2) shorter
life span of red cells; and (3) blood loss.2 Often, these functional
disturbances are not mutually exclusive but are rather intrin-
sically integrated. For example, pathway B, which is the bone
of contention, is involved in a majority of the highlighted risk
factors. Hence, all of the hemolytic conditions, oxidative
diseases, nutritional deﬁciencies, malignancies, viral infections,
and hyperparathyroidism, are partly mediated by a shorter
red cell survival (see Table 1).2
I am not surprised that most of the subjects in the study
reported by the authors failed to meet the criteria for EPO
resistance.3 The study group is selective, excluding patients
with pathologies that are likely to cause EPO-resistant anemia
as deﬁned.2,3 To enhance its predictive value, the deﬁnition
was deliberately restrictive. If we use red cell survival as a
criterion, depending on the cutoff values, no doubt the
majority of renal patients with end stage kidney disease will
be deemed EPO resistant.3,4 Moreover, as indicated in
the article, application of this deﬁnition must take cognizance
of the demographic and clinical variables of the study
population.2
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Table 1 | Etiological factors of erythropoietin resistance that are mediated by poor erythrocyte survival
Poor erythrocyte survival
Clinical entities Highly likely Less likely Least likely
Hemolysis: AIHA, HUS, G6PD, HbS, sepsis, hypersplenism +
Oxidative stress: surgery, HD +
Viral infections: AIDS, CMV, EBV, hepatitis ± ± ±
Malignancy +
Drugs: chemotherapy, ISA +
Fe, folate, vit B12, vit C, vit E, carnitine, and Cu deficiency ± ±
Alcoholism +
Heavy metal toxicity: aluminum, lead +
Pro-inflammatory: poor dialysis, HD, SLE, failed transplant ± +
Hyperparathyroidism +
Abbreviations: þ , yes;±, yes, effect varies with clinical entities; AIDS, acquired immunodeficiency syndrome; AIHA, autoimmune hemolytic anemia; CMV, cytomegalovirus;
Cu, copper; Fe, iron; folate, folic acid; G6PD, glucose 6nn-phosphate dehydrogenase deficiency; HbS, hemoglobin S; HD, hemodialysis; HPTH, hyperparathyroidism;
HUS, hemolytic uremia syndrome; ISA, immunosuppressive agents; SLE, systemic lupus erythematosus; vit, vitamin.
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